The randomized, double-blind and placebo-controlled crossover study observed EpiCor’s effects on immune cells in vivo, with specific focus on NK cell activation, antioxidant status and key immunomodulating agents (cytokines) in a short timeframe.
Blood samples from 12 healthy adults were taken at baseline, and 1 and 2 hours after a 500 mg oral dose of either EpiCor or placebo. Results after 1 hour showed increased activation of NK cell populations and a rapid increase in interferon-γ, a key messenger molecule of the immune system. Effects noted at 2 hours included significant serum antioxidant increases.
The increased levels of some key biomarkers as shown in this study shed light on mechanisms of action that help explain the reduction in cold and flu symptoms seen in earlier clinical studies,” said Larry Robinson, PhD, study coauthor and vice president of scientific affairs for Embria. For further information: www.embriahealth.com